Author/Editor		Jarc, Maja; Ramšak, Darja; Petrovič, Božica
Title		Primerjava podkožnega in intravenskega zdravljenja z eritropoetinom pri bolnikih, zdravljenih s hemodializo, v Splošni bolnišnici Maribor
Translated title		Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis treated in General hospital Maribor
Type		članek
Source		In: Pečovnik-Balon B, editor. Zbornik predavanj Strokovni simpozij z mednarodno udeležbo ob 30. obletnici Oddelka za dializo Splošne bolnišnice Maribor; 2004 feb 6-7; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year		2004
Volume		str. 69-75
Language		slo
Abstract		Background. Recombinant human erythropoetin is used in the management of anemia in patients with chronic and end-stage renal failure. It can be administered subcutaneouslly or intravenously. It has become clear that severe immune adverse effect are associated with subcutaneous route of administration. The most serious adverse effect is pure red cell aplasia. Several studies have suggested that higher doses were needed for the same effect, if erythropoetin is administered intravenously. Methods and results. We have examined patients treating with hemodialysis in General Hospital Maribor and we found out, that they were receiving the same doses of erythropoetin, but the effect of treatment was lower in the intravenously treating group of patients.
Descriptors		KIDNEY FAILURE, CHRONIC HEMODIALYSIS ANEMIA ERYTHROPOIETIN, RECOMBINANT ANEMIA, APLASTIC INJECTIONS, SUBCUTANEOUS INJECTIONS, INTRAVENOUS